|
WO03007867A2
|
|
A salt/ion pair medicinal aerosol formulation
|
|
AU8343801A
|
|
A method of stabilizing a dry powder pharmaceutical formulation
|
|
AU8128801A
|
|
Modulated release therapeutic aerosols
|
|
AU5745601A
|
|
A core formulation
|
|
US6551578B2
|
|
Modulated release particles for aerosol delivery
|
|
US6403121B1
|
|
Core formulation
|
|
US6596262B2
|
|
Modulated release particles for aerosol delivery
|
|
US6749845B2
|
|
Modulated release particles for lung delivery
|
|
US6485707B2
|
|
Modulated release particles for aerosol delivery
|
|
US6475468B2
|
|
Modulated release particles for aerosol delivery
|
|
US6544497B2
|
|
Modulated release particles for aerosol delivery
|
|
US6524621B2
|
|
Core formulation
|
|
US6451342B2
|
|
Core formulation comprised of troglitazone and a biguanide
|
|
US6461639B2
|
|
Core formulation
|
|
MXPA02007187A
|
|
A medicinal aerosol formulation.
|
|
AU4712301A
|
|
A medicinal aerosol formulation
|
|
US6610272B1
|
|
Medicinal aerosol formulation
|
|
US6540983B1
|
|
Medical aerosol formulation
|
|
US6548049B1
|
|
Medicinal aerosol formulation
|
|
US6565833B1
|
|
Medicinal aerosol formulation
|
